RU2007111484A - Составы, содержащие пиперациллин, тазобактам и аминокарбоновую кислоту в растворителе лактата натрия - Google Patents
Составы, содержащие пиперациллин, тазобактам и аминокарбоновую кислоту в растворителе лактата натрия Download PDFInfo
- Publication number
- RU2007111484A RU2007111484A RU2007111484/15A RU2007111484A RU2007111484A RU 2007111484 A RU2007111484 A RU 2007111484A RU 2007111484/15 A RU2007111484/15 A RU 2007111484/15A RU 2007111484 A RU2007111484 A RU 2007111484A RU 2007111484 A RU2007111484 A RU 2007111484A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- composition according
- salt
- range
- content
- Prior art date
Links
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 title claims 6
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 title claims 2
- 239000001540 sodium lactate Substances 0.000 title claims 2
- 229940005581 sodium lactate Drugs 0.000 title claims 2
- 235000011088 sodium lactate Nutrition 0.000 title claims 2
- 239000002904 solvent Substances 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 150000003839 salts Chemical class 0.000 claims 7
- 229940126575 aminoglycoside Drugs 0.000 claims 4
- 239000008156 Ringer's lactate solution Substances 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 229960002292 piperacillin Drugs 0.000 claims 3
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 claims 3
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 claims 3
- 229960003865 tazobactam Drugs 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 2
- 229960003330 pentetic acid Drugs 0.000 claims 2
- FCKYPQBAHLOOJQ-NXEZZACHSA-N 2-[[(1r,2r)-2-[bis(carboxymethyl)amino]cyclohexyl]-(carboxymethyl)amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)[C@@H]1CCCC[C@H]1N(CC(O)=O)CC(O)=O FCKYPQBAHLOOJQ-NXEZZACHSA-N 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- RXDLGFMMQFNVLI-UHFFFAOYSA-N [Na].[Na].[Ca] Chemical group [Na].[Na].[Ca] RXDLGFMMQFNVLI-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical class [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- JVKAWJASTRPFQY-UHFFFAOYSA-N n-(2-aminoethyl)hydroxylamine Chemical compound NCCNO JVKAWJASTRPFQY-UHFFFAOYSA-N 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical group O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 claims 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61887204P | 2004-10-14 | 2004-10-14 | |
| US60/618,872 | 2004-10-14 | ||
| US71917705P | 2005-09-22 | 2005-09-22 | |
| US60/719,177 | 2005-09-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007111484A true RU2007111484A (ru) | 2008-11-20 |
Family
ID=35520532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007111484/15A RU2007111484A (ru) | 2004-10-14 | 2005-10-12 | Составы, содержащие пиперациллин, тазобактам и аминокарбоновую кислоту в растворителе лактата натрия |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20060084639A1 (es) |
| EP (1) | EP1799209A1 (es) |
| JP (1) | JP2008516967A (es) |
| KR (1) | KR20070110256A (es) |
| AU (1) | AU2005295644A1 (es) |
| BR (1) | BRPI0516583A (es) |
| CA (1) | CA2581303A1 (es) |
| CR (1) | CR9056A (es) |
| EC (1) | ECSP077387A (es) |
| IL (1) | IL182354A0 (es) |
| MX (1) | MX2007004490A (es) |
| NO (1) | NO20071711L (es) |
| RU (1) | RU2007111484A (es) |
| WO (1) | WO2006044600A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101129382B (zh) * | 2006-08-25 | 2013-12-25 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和缓冲组分的抗生素复方 |
| ITMI20070568A1 (it) | 2007-03-22 | 2008-09-23 | Acs Dobfar Spa | Comosizione farmaceutica sterile iniettabile avente piperacillina sodica e tazobactam sodico come principi attivi |
| US20090075966A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched tazobactam |
| JP5639471B2 (ja) * | 2008-07-28 | 2014-12-10 | 惠三 山口 | 感染症治療効果増強剤 |
| PE20140716A1 (es) | 2010-11-25 | 2014-07-12 | Allecra Therapeutics Gmbh | Compuestos y su usos |
| HUE070342T2 (hu) | 2011-09-09 | 2025-05-28 | Merck Sharp & Dohme Llc | Ceftolozan/tazobactam intrapulmonális infekciók kezelésére |
| WO2013042140A2 (en) * | 2011-09-23 | 2013-03-28 | Manu Chaudhary | Non antibiotic,non peptide compounds for antibiotic efficacy & safety enhancement |
| US8809314B1 (en) | 2012-09-07 | 2014-08-19 | Cubist Pharmacueticals, Inc. | Cephalosporin compound |
| US8476425B1 (en) | 2012-09-27 | 2013-07-02 | Cubist Pharmaceuticals, Inc. | Tazobactam arginine compositions |
| US9872906B2 (en) | 2013-03-15 | 2018-01-23 | Merck Sharp & Dohme Corp. | Ceftolozane antibiotic compositions |
| AU2014227660B2 (en) | 2013-03-15 | 2014-11-06 | Merck Sharp & Dohme Llc | Ceftolozane antibiotic compositions |
| US20140274997A1 (en) | 2013-03-15 | 2014-09-18 | Cubist Pharmaceuticals, Inc. | Cephalosporin pharmaceutical compositions |
| WO2015035376A2 (en) | 2013-09-09 | 2015-03-12 | Calixa Therapeutics, Inc. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
| US8906898B1 (en) | 2013-09-27 | 2014-12-09 | Calixa Therapeutics, Inc. | Solid forms of ceftolozane |
| WO2022106611A1 (en) * | 2020-11-20 | 2022-05-27 | Xellia Pharmaceuticals Aps | Novel compositions of beta-lactam compounds |
| WO2022106630A1 (en) * | 2020-11-20 | 2022-05-27 | Xellia Pharmaceuticals Aps | Stable formulations comprising piperacillin and/or tazobactam |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4562073A (en) * | 1982-12-24 | 1985-12-31 | Taiho Pharmaceutical Company Limited | Penicillin derivatives |
| US6207661B1 (en) * | 1999-02-22 | 2001-03-27 | Baxter International Inc. | Premixed formulation of piperacillin sodium and tazobactam sodium injection |
| US20020132220A1 (en) * | 2000-12-27 | 2002-09-19 | Berens Kurt L. | Use of selectin antagonists in organ preservation solutions |
| EP1499341A4 (en) * | 2002-04-18 | 2010-10-27 | Univ Iowa Res Found | METHOD FOR INHIBITING AND TREATING BACTERIAL BIOFILMS WITH METAL CHELATE IMAGES |
| JP2006516084A (ja) * | 2002-06-27 | 2006-06-22 | セントカー・インコーポレーテツド | Ｃｎｇｈ０００４ポリペプチド、抗体、組成物、方法および使用 |
| US6900184B2 (en) * | 2003-04-14 | 2005-05-31 | Wyeth Holdings Corporation | Compositions containing pipercillin and tazobactam useful for injection |
| AU2003230899A1 (en) * | 2003-04-14 | 2004-11-26 | Wyeth Holdings Corporation | Compositions containing piperacillin and tazobactam useful for injection |
| RU2322980C2 (ru) * | 2003-04-14 | 2008-04-27 | Уайт Холдингз Корпорейшн | Композиции, содержащие пиперациллин и тазобактам, применимые для инъекции |
-
2005
- 2005-10-12 JP JP2007536916A patent/JP2008516967A/ja not_active Withdrawn
- 2005-10-12 WO PCT/US2005/036938 patent/WO2006044600A1/en not_active Ceased
- 2005-10-12 RU RU2007111484/15A patent/RU2007111484A/ru not_active Application Discontinuation
- 2005-10-12 CA CA002581303A patent/CA2581303A1/en not_active Abandoned
- 2005-10-12 BR BRPI0516583-0A patent/BRPI0516583A/pt not_active IP Right Cessation
- 2005-10-12 MX MX2007004490A patent/MX2007004490A/es unknown
- 2005-10-12 KR KR1020077010612A patent/KR20070110256A/ko not_active Withdrawn
- 2005-10-12 AU AU2005295644A patent/AU2005295644A1/en not_active Abandoned
- 2005-10-12 EP EP05807860A patent/EP1799209A1/en not_active Withdrawn
- 2005-10-14 US US11/250,716 patent/US20060084639A1/en not_active Abandoned
-
2007
- 2007-03-30 NO NO20071711A patent/NO20071711L/no not_active Application Discontinuation
- 2007-04-01 IL IL182354A patent/IL182354A0/en unknown
- 2007-04-11 EC EC2007007387A patent/ECSP077387A/es unknown
- 2007-04-13 CR CR9056A patent/CR9056A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0516583A (pt) | 2008-09-16 |
| MX2007004490A (es) | 2007-05-08 |
| CA2581303A1 (en) | 2006-04-27 |
| CR9056A (es) | 2007-09-07 |
| WO2006044600A1 (en) | 2006-04-27 |
| US20060084639A1 (en) | 2006-04-20 |
| JP2008516967A (ja) | 2008-05-22 |
| ECSP077387A (es) | 2007-05-30 |
| KR20070110256A (ko) | 2007-11-16 |
| IL182354A0 (en) | 2007-09-20 |
| EP1799209A1 (en) | 2007-06-27 |
| AU2005295644A1 (en) | 2006-04-27 |
| NO20071711L (no) | 2007-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007111484A (ru) | Составы, содержащие пиперациллин, тазобактам и аминокарбоновую кислоту в растворителе лактата натрия | |
| CA2619441C (en) | Acetylcysteine composition and uses therefor | |
| RU2008138266A (ru) | Составы для парентерального введения лекарств и их применения | |
| NO974163D0 (no) | Ester av 5-aminolevulinsyre som fotosensibiliserings-middel i fotokjemoterapi | |
| RU2007136046A (ru) | Лекарственные формы ризедроната | |
| ATE538774T1 (de) | Pharmazeutische formulierungen und verfahren zur behandlung von atemwegsinfektionen | |
| DK1227806T3 (da) | Farmaceutisk præparat indeholdende tolterodin og dets anvendelse | |
| RU2008103617A (ru) | Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза | |
| AU2011281035A1 (en) | Acetycysteine compositions and methods of use thereof | |
| NZ544645A (en) | Use of calcitonin in osteoarthritis | |
| CA2564886A1 (en) | Nutritional composition for enhancing lean muscle stimulus, growth, strength and recovery, creating and prolonging intense muscle pumps, supporting endurance, strength, performance, size and stamina, providing a transducer effect for nitric oxide, increasing nutrient delivery and/or promoting increased vascular response in an individual | |
| JP2009173684A (ja) | 腎臓結石疾患の予防のための希土類化合物の使用 | |
| CA2311024C (en) | Pharmaceutical composition for oral administration of chelating agents | |
| AR046410A1 (es) | Composiciones farmaceuticas para la liberacion modificada de modafinilo | |
| CA2565993A1 (en) | Salt of 4-or 5- aminosalicylic acid | |
| BRPI0411455A (pt) | composto, formulação farmacêutica, método de tratamento ou prevenção de distúrbios de lipìdeo, uso de um composto, método de tratamento de diabetes do tipo 2, e, composição farmacêutica | |
| NO20024673L (no) | Farmasöytisk sammensetning med kontrollert frigivning for oral anvendelse inneholdende midodrin og/eller desglymidodrin | |
| AU2011202871B2 (en) | Acetylcysteine composition and uses therefor | |
| US6720356B2 (en) | Magnesium di-potassium EDTA complex and method of administration | |
| RU2001112325A (ru) | Способ коррекции маточного кровотока | |
| UY27472A1 (es) | Metodo para la preparación de una composición farmacéutica que comprende un acido-5-amino-salicilico, para uso en el tratamiento de la colitis ulcerosa y enfermedad de crohn. | |
| SE0000782D0 (sv) | Pharmaceutical formulation and its use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20100816 |